In the present prospective study, 68Ga-PSMA-11 PET/CT accurately localized the primary prostatic lesion and metastasis in treatment-naïve prostate cancer patients, and significantly improved detection rate of the malignant lesions in patients with mCRPC, even when PSA levels were low. The gene discussed is FOLH1; the disease is prostate carcinoma.